Introduction
Cisplatin (CDDP) is a principal compo nent of standard ovarian cancer chemother apy. However, the frequent development of cellular resistance to CDDP severely restricts the clinical therapeutic success. The molecu lar mechanisms of resistance are manifold and not completely understood [1] .
Previously, we reported that liposo mal CDDP overcomes CDDP resistance of A2780cis human ovarian cancer cells [2] . However, the superior cytotoxic activi ty of liposomal CDDP vs. the free drug in A2780cis cells did not correlate with DNA platination levels, thus suggesting a different mode of action of liposomal CDDP com pared to free CDDP.
To gain an insight into liposomal CDDP activity, a transcriptome analysis of A2780cis cells, either untreated, or in response to ex posure with IC50 values of free or liposomal CDDP has been performed [3] . A process network analysis of upregulated genes indi cated that liposomal CDDP induced a highly different gene expression profile compared to the free drug. p53 was identified as play ing a key role in directing transcriptional responses to free or liposomal CDDP. Most interestingly, the transcriptome data showed that liposomal CDDP, in contrast to the free drug, induces expression of genes from the extrinsic pathway of apoptosis, which indi cates how liposomal CDDP can overcome chemoresistance of A2780cis cells.
The aim of this study was to gain further insight into liposomal CDDP activity and to confirm prior findings on apoptosis induction on a protein and functional level.
Materials and methods

Cell lines
The human ovarian carcinoma cell line A2780 as well as CDDPresistant A2780cis cells were obtained from the European Col lection of Cell Cultures. They were cultured in RPMI1640 medium with a 10% FCS, 1.5% Lglutamine and 1% penicillin/strepto mycin supplement (PAN Biotech).
Liposome preparation
CDDP liposomes were prepared from soy phosphatidylcholine (SPC), choles terol (Chol) and 1,2distearoylsnglycero 3phosphoethanolamineN[methoxy (poly ethylene glycol)2000] (ammonium salt) (mPEGPE) in a 65 : 30 : 5 molar ratio by hydration technique as described [2] . They were characterized by determining particle size and ζ-potential (Autosizer 2c, Malvern; Zetatrac, Microtrac), as well as phospholipid and CDDP concentration by fAAS as indi cated [2] . SPC was purchased from Lipoid AG, mPEGPE from Genzyme Pharmaceuti cals, and Chol and CDDP were from Sigma Aldrich Chemie.
Apoptosis array -proteome profiler™
CDDP resistant cells (A2780cis) were treated with 2 µmol/L of either free or li posomal CDDP, or empty liposomes in a total lipid concentration corresponding to 
Determination of CDDP toxicity
The toxicity of free and liposomal CDDP in A2780cis cells was detected by the MTT (3(4,5dimethylthiazole2yl)2,5diphenyl tetrazolium bromide) assay as indicated be fore [2] . CDDP was used in concentrations from 10 -3.5 mol/L to 10 -7.5 mol/L, covering the typical IC 50 range of A2780 and A2780cis cells known from previous experiments.
To evaluate the kind of apoptosis pathway contributing to CDDP cell toxicity, different in hibitors of p53 dependent caspases were added. Since caspase8 is pivotal for the extrinsic apop tosis pathway, and caspase-9 reflects mitochon drial intrinsic apoptotic activity [4] , the effect of the caspase8 inhibitor ZIETDFMK and caspase9 inhibitor ZLEHDFMK, compared to the caspase3 inhibitor ZDEVDFMK (all purchased from R&D Systems) on cytotoxicity of free and liposomal CDDP was investigated. Therefore, 20,000 cells were seeded in 100 µl/ well in 96well plates, while part of the cells were preincubated with 50 µmol/L caspase3, 8 or 9 inhibitors for 3 hours before the CDDP treatment. After 72 hours of incubation (37 °C, 5% CO 2 ) the absorption of each sample was measured.
Statistics
The apoptosis antibodyarray was per formed in duplicates, which individually differed by less than 5.4% RSD. A one way ANOVA was performed proving changes in protein regulation significantly different (p < 0.001).
The experiments on CDDP toxicity were arranged in triplicates and results were pre sented as mean values, which significantly vary in characteristics as shown by two way ANOVA (p < 0.0001).
Results
CDDP-dependent apoptosis in A2780cis cells
We have recently reported that liposo mal CDDP induces remarkably different gene expression profiles in CDDP-resistant A2780cis cells compared to the free drug [3] . This illustrated that liposomal cell entry of CDDP has important consequences for intracellular trafficking of the drug and the affected cellular targets, in comparison to the free drug. p53 was identified as an essential factor for mediating transcriptional respons es after exposure to free or liposomal CDDP. While the free drug induced expression of es sential genes of the intrinsic apoptosis path way (BAX, BID, CASP9) most likely through p38MAPK activation, liposomal CDDP in duced expression of genes of the extrinsic pathway of apoptosis (TNFRSF10B-DR5,
CD70-TNFSF7).
In order to confirm these gene expres sion data at the level of protein, the present study analyzed (i) the semiquantitative mea surement of apoptosis proteins and (ii) their functional activity in response to free and li posomal CDDP treatment.
To address this issue, an apoptosis pro teome profiler antibody-array was used. A2780cis cells were exposed to IC50 concen trations of free or liposomal CDDP and the corresponding cell lysates were used for pro teome profiler antibody-arrays. The data were then compared with untreated A2780cis cells.
As shown in Figure 1 (left panel), both, li posomal and free CDDP induced an upregu lation of cleaved caspase3 protein which indicates cytotoxic and apoptotic effects, since caspase3 is a downstream effector of intrinsic and extrinsic pathways of apopto sis. These results are specific for CDDP as empty liposomes did not significantly induce cleaved caspase 3.
Interestingly, free CDDP caused signifi cant upregulation of cytochrome C (~ 30%) and BAX (~ 10%) proteins, which are in volved in intrinsic (mitochondrial) apopto sis [5] . On the other hand, Fas and FADD as indicators for early apoptosis and sensors for extracellular stimuli and downstream signaling [6] were not induced by the free drug. These findings show that treatment of A2780cis cells with free CDDP results in activation of the intrinsic pathway of apop tosis, which is in line with results from the literature [5] .
Our recent gene expression data sug gested that liposomal CDDP may induce the extrinsic pathway of apoptosis. In this con text, it is interesting to note that treatment of A2780cis cells with liposomal CDDP did not significantly affect the expression of Bad, BAX and cytochrome C proteins which are essential regulators of the intrinsic pathway of apoptosis (Figure 1, left panel) . On the other hand, the expression of Fas protein was downregulated after exposure to free CDDP, but no significant alteration of FAS expres sion after liposomal CDDP treatment was evident. Fas is a cell surface death receptor and important activator of the extrinsic path way of apoptosis [4] .
Taken together, these data provide experi mental evidence that liposomal CDDP can selectively activate the extrinsic pathway of apoptosis in CDDPresistant A2780cis cells. We consider this as an important mechanism of overcoming CDDP resistance of ovarian cancer cells.
We noted that treatment of A2780cis cells with empty liposomes has certain effects on the expression of "apoptosisregulating" proteins. These are shown in Figure 1 in the empty liposome column.
The extrinsic pathway of apoptosis is selectively activated by liposomal CDDP in A2780cis cells
Next, we wished to investigate the effects of free and liposomal CDDP on apoptotic processes in A2780cis cells using specific caspase inhibitors. We thus performed MTT assays of A2780cis cells after treatment with free or liposomal CDDP in the presence of diverse caspase inhibitors (Figure 1, right  panel) . The MTTassay measures IC50 val ues of CDDP. When apoptosis is inhibited by caspase inhibitors, more CDDP will be needed to achieve an IC50. Caspase3 is a downstream effector of both the intrinsic and extrinsic pathways of apoptosis. We treated A2780cis cells with free and liposomal CDDP in the presence of a caspase3 inhibi tor (Figure 1, right panel) and the MTT assay showed similar IC50 values. Caspase8 is specific for the extrinsic pathway of apopto sis. We performed MTT assays of A2780cis after treatment with free and liposomal CDDP in the presence of a caspase8 inhibi tor. Figure 1 (right panel) shows a significant difference. A much higher amount of liposo mal CDDP was needed to achieve an IC50 than that of free CDDP. This result demon strates that liposomal CDDP activates the extrinsic pathway of apoptosis in A2780cis cells. Next, we performed MTT assays in the presence of a caspase9 inhibitor. Caspase9 is an essential component of the intrinsic pathway of apoptosis. Figure 1 (right panel) shows that a significant higher concentration of free CDDP was necessary to achieve an IC50 concentration than that of liposomal CDDP. This result clearly demonstrates that free CDDP activates the intrinsic (mitochon drial) pathway of apoptosis in A2780cis cells. This result is in line with data from the literature [5] . Taken together our results show a selective activation of the extrinsic pathway of apoptosis by liposomal CDDP in CDDP resistant A2780cis ovarian cancer cells. The data provide an explanation, how liposomal CDDP can overcome CDDP resis tance of A2780cis ovarian cancer cells.
Conclusion
Liposomes have been considered as promising, but passive carriers in medical sciences to mediate a controlled transport of a drug cargo to target sites or into target cells. Here, we provide evidence that a lipo somal drug transport into cells might have stronger consequences for directing the drug activity beyond a simple transport function. Liposomal CDDP induces programmed cell death via the extrinsic pathway of apoptosis, which is in contrast to the drug taken up in free form. It thus appears that this is the key to explain, why liposomal CDDP overcomes cellular resistance regimes in A2780cis cells. These findings shed new light on liposomal drug carrier approaches in cancer and sug gest liposomal CDDP as promising strategy for the treatment of CDDP resistant ovarian carcinomas.
